KRAS mutations in patients with colorectal cancer in Libya

Abudabous,Asma; Drah,Mustafa; Aldehmani,Mamdouh; Parker,Iqbal; Alqawi,Omar

doi:10.3892/mco.2021.2359

KRAS mutations in patients with colorectal cancer in Libya

Authors:
- Asma Abudabous
- Mustafa Drah
- Mamdouh Aldehmani
- Iqbal Parker
- Omar Alqawi
View Affiliations

Affiliations: Department of Life Sciences, The Libyan Academy, Misurata 218-51, Libya, Department of Zoology, Faculty of Science, Misurata University, Misurata 218-51, Libya, National Cancer Institute‑Misurata, Misurata 218-51, Libya, Department of Integrative Biomedical Sciences and Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town 7925, South Africa, Biotechnology Research Centre, National Cancer Institute‑Misurata, Misurata 218-51, Libya
Published online on: July 30, 2021 https://doi.org/10.3892/mco.2021.2359
Article Number: 197
Copyright: © Abudabous et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Large prospective clinical trials have demonstrated that colorectal cancers (CRCs) with wild‑type KRAS respond favorably to anti‑epidermal growth factor receptor treatment, thus making mutational analysis obligatory prior to treatment. In our study, frozen CRC tissues from Libyan patients were analyzed for KRAS and HRAS mutations in codons 12/13 by direct sequencing and the correlations with clinical and pathological parameters were investigated. A total of 34 CRC cases, comprising 19 men and 15 women (age range, 24‑87 years), were subjected to systematic analysis for RAS mutations. Although HRAS mutations were not detected in any of the patients in the study group, KRAS codon 12/13 mutations were present in 38.2% (13/34) of the patients. The frequent types of codon 12 mutations were glycine to aspartate (G12D, 46.1%); glycine to valine (G12V, 30.8%) and glycine to cysteine (G12C, 15.4%), while the codon 13 mutations were glycine to aspartate (G13D, 7.7%). G→A mutations occurred in 53.8% (7/13) of the patients, while G→T mutations occurred in 46.2% (6/13) of the patients. Mutations occurred at the first base of codon 12 or 13 in 2/13 (15.4%) and at the second base in 11/13 (84.6%) patients. There was no significant association between clinicopathological characteristics and KRAS mutation status, except the site of the tumors harboring KRAS mutations, which was as follows: The frequency was higher among tumors located in the left colon (8/13, 61.5%) compared to other sites (P=0.027). KRAS mutations were correlated with advanced age, with 10/13 being aged >50 years and affected 8/15 female patients (53%) compared with 5/19 male patients (26%). The highest frequency of KRAS mutations was observed in highly differentiated CRCs (8/13).

View Figures

View References

1	Al-Sohaily S, Biankin A, Leong R, Kohonen-Corish M and Warusavitarne J: Molecular pathways in colorectal cancer. J Gastroenterol Hepatol. 27:1423–1431. 2012.PubMed/NCBI View Article : Google Scholar
2	Ivanovich JL, Read TE, Ciske DJ, Kodner IJ and Whelan AJ: A practical approach to familial and hereditary colorectal cancer. Am J Med. 107:68–77. 1999.PubMed/NCBI View Article : Google Scholar
3	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. 2016.PubMed/NCBI View Article : Google Scholar
4	Fearon ER and Vogelstein B: A genetic model for colorectal tumourigenesis. Cell. 61:759–767. 1990.PubMed/NCBI View Article : Google Scholar
5	Lengauer C, Kinzler KW and Vogelstein B: Genetic instabilities in human cancers. Nature. 396:643–649. 1998.PubMed/NCBI View Article : Google Scholar
6	Vogelstein B and Kinzler KW: Lessons from hereditary colorectal cancer. Cell. 87:159–170. 1996.PubMed/NCBI View Article : Google Scholar
7	Arrington A, Heinrich E, Lee W, Duldulao M, Patel S, Sanchez J, Garcia-Aguilar J and Kim J: Prognostic and predictive roles of KRAS mutation in colorectal cancer. Int J Mol Sci. 13:12153–12168. 2012.PubMed/NCBI View Article : Google Scholar
8	Baines AT, Xu D and Der CJ: Inhibition of ras for cancer treatment: The search continues. Future Med Chem. 3:1787–1808. 2011.PubMed/NCBI View Article : Google Scholar
9	Bamford S, Dawson E, Forbes S, Clements J, Pettett R, Dogan A, Flanagan A, Teague J, Futreal PA, Stratton MR and Wooster R: The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer. 91:355–358. 2004.PubMed/NCBI View Article : Google Scholar
10	Tan C and Du X: KRAS mutation testing in metastatic colorectal cancer. World J Gastroenterol. 18:5171–5180. 2012.PubMed/NCBI View Article : Google Scholar
11	Prior IA, Lewis PD and Mattos C: A comprehensive survey of ras mutations in cancer. Cancer Res. 72:2457–2467. 2012.PubMed/NCBI View Article : Google Scholar
12	Jančík S, Drábek J, Radzioch D and Hajdúch M: Clinical relevance of KRAS in human cancers. J Biomed Biotechmol. 2010(150960)2010.PubMed/NCBI View Article : Google Scholar
13	Gideon P, John J, Frech M, Lautwein A, Clark R, Scheffler JE and Wittinghofer A: Mutational and kinetic analyses of the GTPase-activating protein (GAP)-p21 interaction: The C-terminal domain of GAP is not sufficient for full activity. Mol Cell Biol. 12:2050–2056. 1992.PubMed/NCBI View Article : Google Scholar
14	Kinzler K and Vogelstein B: The genetic basis of cancer. In: Cancer Gene Therapy. Curiel DT and Douglas JT (eds). Humana Press, Totowa, pp9-18, 2002.
15	Lee S, Brophy VH, Cao J, Velez M, Hoeppner C, Soviero S and Lawrence HJ: Analytical performance of a PCR assay for the detection of KRAS mutations (codons 12/13 and 61) in formalin-fixed paraffin-embedded tissue samples of colorectal carcinoma. Virchows Arch. 460:141–149. 2012.PubMed/NCBI View Article : Google Scholar
16	Bader T and Ismail A: Higher prevalence of KRAS mutations in colorectal cancer in Saudi Arabia: Propensity for lung metastasis. Alexandria J Med. 50:203–209. 2014.
17	Andreyev HJ, Norman AR, Clarke PA, Cunningham D and Oates J: Kirsten ras mutations in patients with colorectal cancer: The multicenter RASCAL study. J Nat Cancer Inst. 90:675–684. 1998.PubMed/NCBI View Article : Google Scholar
18	Zekri J, Rizvi A, Al-Maghrabi J and Bin Sadiq B: K-Ras in colorectal cancer tumors from Saudi patients: Frequency, clinicopathological association and clinical outcome. Open Colorectal Cancer J. 5:22–27. 2012.
19	Abubaker J, Bavi P, Al-Haqawi W, Sultana M, Al-Harbi S, Al-Sanea N, Abduljabbar A, Ashari LH, Alhomoud S, Al-Daye F, et al: Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma. J Pathol. 219:435–445. 2009.PubMed/NCBI View Article : Google Scholar
20	Gorukmez O, Yakut T, Gorukmez O, Sag SO, Karkucak M and Kanat O: Distribution of KRAS and BRAF mutations in metastatic colorectal cancers in Turkish patients. Asian Pac J Cancer Prev. 17:1175–1179. 2016.PubMed/NCBI View Article : Google Scholar
21	Smith G, Carey FA, Beattie J, Wilkie MJ, Lightfoot TJ, Coxhead J, Garner RC, Steele RJ and Wolf C: Mutations in APC, Kirsten-ras, and p53-alternative genetic pathways to colorectal cancer. Proc Natl Acad Sci. 99:9433–9438. 2002.PubMed/NCBI View Article : Google Scholar
22	Aissi S, Buisine M, Zerimech F, Kourda N, Moussa A, Manai M and Porchet N: KRAS mutations in colorectal cancer from Tunisia: Relationships with clinicopathological variables and data on TP53 mutations and microsatellite instability. Mol Biol Rep. 40:6107–6112. 2013.PubMed/NCBI View Article : Google Scholar
23	Edkins S, O'Meara S, Parker A, Stevens C, Reis M, Jones S, Greenman C, Davies H, Dalgliesh G, Forbes S, Hunter C, et al: Recurrent KRAS codon 146 mutations in human colorectal cancer. Cancer Biol Ther. 5:928–932. 2006.PubMed/NCBI View Article : Google Scholar
24	Licar A, Cerkovnik P, Ocvirk J and Novakovic S: KRAS mutations in Slovene patients with colorectal cancer: Frequency, distribution and correlation with the response to treatment. Int J Oncol. 36:1137–1144. 2010.PubMed/NCBI View Article : Google Scholar
25	Zekri J, Al-Shehri A, Mahrous M, Al-Rehaily S, Darwish T, Bassi S, El Taani H, Al Zahrani A, Elsamany S, Al-Maghrabi J and Sadiq BB: Mutations in codons 12 and 13 of K-ras exon 2 in colorectal tumors of Saudi Arabian patients: Frequency, clinicopathological associations, and clinical outcomes. Genet Mol Res. 16(4238)2017.PubMed/NCBI View Article : Google Scholar
26	Beg S, Siraj A, Prabhakaran S, Bu R, Al-Rasheed M, Sultana M, Qadri Z, Al-Assiri M, Sairafi R, Al-Sanea N, et al: Molecular markers and pathway analysis of colorectal carcinoma in the Middle East. Cancer. 121:3799–3808. 2015.PubMed/NCBI View Article : Google Scholar
27	Dallol A, Buhmeida A, Al-Ahwal MS, Al-Maghrabi J, Bajouh O, Al-Khayyat S, Alam R, Abusanad A, Turki R, Elaimi A, et al: Clinical significance of frequent somatic mutations detected by high-throughput targeted sequencing in archived colorectal cancer samples. J Transl Med. 14(118)2016.PubMed/NCBI View Article : Google Scholar
28	Sammoud S, Khiari M, Semeh A, Amine L, Ines C, Amira A, Lilia K, Taher K, Sabeh M and Saadia B: Relationship between expression of ras p21 oncoprotein and mutation status of the K-ras gene in sporadic colorectal cancer patients in Tunisia. Applied Immunohistochem Mol Morphol. 20:146–152. 2012.PubMed/NCBI View Article : Google Scholar
29	Aissi S, Buisine M, Zerimech F, Kourda N, Moussa A, Manai M and Porchet N: Somatic molecular changes and histopathological features of colorectal cancer in Tunisia. World J Gastroenterol. 19:5286–5294. 2013.PubMed/NCBI View Article : Google Scholar
30	Elbjeirami W and Sughayer M: KRAS mutations and subtyping in colorectal cancer in Jordanian patients. Oncol Lett. 4:705–710. 2012.PubMed/NCBI View Article : Google Scholar
31	Gumus M, Dane F, Karabulut B, Uygun K, Orhan B, Aydin K and Ozen R: Interim results of observational study to determine K-ras mutation rates in patients with metastatic colorectal cancer in Turkey. Eur J Cancer. 49 (Suppl):S571. 2013.
32	Elsabah M and Adel I: Immunohistochemical assay for detection of K-ras protein expression in metastatic colorectal cancer. J Egypt Nat Cancer Inst. 25:51–56. 2013.PubMed/NCBI View Article : Google Scholar